Immune cell army targets childhood cancers in new trial
NCT ID NCT05400603
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has not responded to standard therapy or has returned. The approach combines specially grown immune cells (gamma delta T cells) from a healthy donor with several chemotherapy drugs and an antibody. The main goals are to find the safest dose of the immune cells and to understand side effects. About 24 children aged 1 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.